Close
ACHEMA MIDDLE EAST 2026

In-Person Meetings To Begin By The FDA Starting February 13

FDA has recently announced that it is going to restart its in-person meetings that are face-to-face beginning February 13 with industry sponsors of biologics...

Medicine Patient Pool For 2023-25 To Curb Drug Inequalities

A novel strategy for 2023–25 adopted by the Medicines Patent Pool looks to lessen the inequalities in access by way of enhancing the affordability...

Acute Leukaemia May Find Saviour In PIK-75, An Existing Drug

National University of Singapore researchers have gone ahead and revisited a drug which they believe can be a problem solver when it comes to...

The Top 3 Questions Looming Over Pharma Sector This 2023

2023 can be challenging for the pharmaceutical sector as it will mark the rollout of certain important drug pricing reforms across the US which...

FDA Comes With A Research Map Concerning Biosimilars Program

The FDA has gone on to release the Biosimilar User Fee Amendments III Regulatory Science Pilot Program, called the Research Roadmap, to give out...

Getting Immunotherapy Work In Case of Pancreatic Cancer

One of the latest studies that takes into account the tumour microenvironment of pancreatic cancer puts forth the cause that tumour cells are resistant...

Monoclonal Antibodies Ideal Against Malaria- Suggests Study

Only one dose of the monoclonal antibody (mAb) CIS43LS gave out high levels of protection against Malaria in challenge study as per new research....

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...